Aetna's Mark Bertolini, Cigna's David Cordani weigh in on mergers, drug costs

Though they are both pursuing mergers with other companies, Cigna CEO David Cordani and Aetna CEO Mark Bertolini recently expressed very similar ideas about the benefits of health insurer consolidation and the importance of shifting to value-based payment models.

In an interview with Bloomberg's Angie Lau, Cordani (right) provided a counter-argument to insurer merger critics such as presidential candidate Hillary Clinton. He said the two insurers' businesses are complementary, as Anthem's strength lies in the individual business, while Cigna's is in the midsize-employer business, the global employer benefit sector and health engagement initiatives.

Bertolini (left) made a similar point during an interview with Fortune's Susie Gharib, noting that there are 400 health insurance companies in the U.S. and that Aetna's commercial-market focus and Humana's Medicare Advantage dominance means the overlap between the two is fairly small. He also pointed out that Blue Cross Blue Shield plans are the dominant player in 30 states, having more than 30 percent, and in some cases, as high as 70 percent, of the market share.

For his part, Cordani also notes that "the headline says you have five [major insurers] shrinking to three, but the reality is you'll have more choices brought to consumers." Cigna and Anthem's deal, he said, will mean more Medicare, Medicaid, small-business and individual plans are available.

Both Cordani and Bertolini also addressed the hot-button issue of high drug prices, expressing support for the concept of insurers paying pharmaceutical companies for value.

"I think we need to have a much tighter connection between the drug itself and the outcome," Bertolini said, adding that there needs to be a less-expensive way of getting prescription drugs to market. Cordani, meanwhile, touted Cigna's outcomes-based contract with Merck and Gilead for specialty drugs, saying that paying for value is the next evolution in healthcare.

Two pharmaceutical CEOs, however, recently expressed doubts about the feasibility of this model becoming mainstream in the U.S.

To learn more:
- here's the Bloomberg interview
- watch the Fortune interview

Related Articles:
Count Clinton among critics of health insurance mergers
Senate panel grills Aetna, Anthem execs on merger deals
CEO Mark Bertolini: Humana deal will help Aetna compete in consumer-driven marketplace
Cigna CEO Cordani: Mergers will increase choice, not decrease affordability
Outcome-based deals with insurers tough to implement, pharma CEOs say
Payers, providers push manufacturers toward value-based deals

Suggested Articles

Rebates for Part D drugs grew from 2011 to 2015 but not enough to offset price spikes, a study found.

Medicare Advantage plans still have time to meet their year-end goals.

A recent digital health conference highlighted the ongoing obstacles to using next-generation technology to impact health outcomes.